[go: up one dir, main page]

ME03631B - Sastavi za isporuku aktivnih agenasa u disajne puteve i povezani postupci i sistemi - Google Patents

Sastavi za isporuku aktivnih agenasa u disajne puteve i povezani postupci i sistemi

Info

Publication number
ME03631B
ME03631B MEP-2020-37A MEP202037A ME03631B ME 03631 B ME03631 B ME 03631B ME P202037 A MEP202037 A ME P202037A ME 03631 B ME03631 B ME 03631B
Authority
ME
Montenegro
Prior art keywords
compositions
systems
active agents
related methods
respiratory administration
Prior art date
Application number
MEP-2020-37A
Other languages
German (de)
English (en)
French (fr)
Inventor
Reinhard Vehring
Michael Steven Hartman
Adrian Edward Smith
Vidya B Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03631(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of ME03631B publication Critical patent/ME03631B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
MEP-2020-37A 2009-05-29 2010-05-28 Sastavi za isporuku aktivnih agenasa u disajne puteve i povezani postupci i sistemi ME03631B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
EP16164849.8A EP3111927B1 (en) 2009-05-29 2010-05-28 Compositions for respiratory delivery of active agents and associated methods and systems

Publications (1)

Publication Number Publication Date
ME03631B true ME03631B (me) 2020-07-20

Family

ID=42269864

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-37A ME03631B (me) 2009-05-29 2010-05-28 Sastavi za isporuku aktivnih agenasa u disajne puteve i povezani postupci i sistemi

Country Status (31)

Country Link
US (12) US20110132357A1 (me)
EP (6) EP3106149B1 (me)
JP (10) JP5873012B2 (me)
KR (7) KR101748892B1 (me)
CN (6) CN102753152B (me)
AR (3) AR076621A1 (me)
AU (3) AU2010253770B9 (me)
BR (3) BRPI1011229B8 (me)
CA (3) CA2763939A1 (me)
CY (8) CY1118030T1 (me)
DK (6) DK3111926T3 (me)
ES (6) ES2774367T3 (me)
FR (1) FR19C1040I2 (me)
HR (6) HRP20161101T1 (me)
HU (8) HUE047823T2 (me)
IL (3) IL216467B (me)
LT (8) LT3106149T (me)
LU (2) LUC00124I2 (me)
ME (1) ME03631B (me)
MX (5) MX350163B (me)
NL (1) NL300995I2 (me)
NO (2) NO2019026I1 (me)
PH (1) PH12017500778A1 (me)
PL (6) PL2435025T3 (me)
PT (6) PT3111926T (me)
RU (5) RU2713404C2 (me)
SI (6) SI3111926T1 (me)
SM (6) SMT202000077T1 (me)
TW (9) TWI707700B (me)
WO (3) WO2010138884A2 (me)
ZA (4) ZA201108275B (me)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
KR101643478B1 (ko) 2005-09-14 2016-07-27 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
CA2643464C (en) 2006-02-22 2018-09-04 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN106039494B (zh) 2008-06-13 2019-12-24 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX336361B (es) 2008-06-20 2015-12-03 Mannkind Corp Un metodo y un aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2582421A1 (en) * 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
AU2011368334A1 (en) * 2011-05-17 2013-11-21 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
EP2836204B1 (en) * 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
CA2897464C (en) * 2013-01-28 2021-05-18 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
WO2014118532A1 (en) * 2013-01-31 2014-08-07 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
PT2964199T (pt) * 2013-03-04 2020-05-12 Besins Healthcare Lu Sarl Composições farmacêuticas secas compreendendo nanoparticulas do agentes ativos, limitadas a partículas transportadoras
WO2014141069A1 (en) * 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2014144894A1 (en) * 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
EP2999460A1 (en) * 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CA2926432A1 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
DK2897589T3 (en) * 2013-11-22 2018-03-12 Teva Branded Pharmaceutical Prod R & D Inc Inhalable drug
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
CN106999496A (zh) * 2014-10-01 2017-08-01 Als山地有限责任公司 含有阿司匹林、二甲双胍和血清素与非离子表面活性剂的医药组合物
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
WO2017108917A1 (en) 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
WO2017157265A1 (zh) * 2016-03-15 2017-09-21 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
BR112018075017A2 (pt) 2016-06-30 2019-03-19 Philip Morris Products S.A. partículas de nicotina
CA3037092C (en) 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
AU2018347970B2 (en) * 2017-10-09 2024-05-30 Pearl Therapeutics, Inc. Drug delivery systems and related methods
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
EP3860580A4 (en) * 2018-10-01 2022-07-20 Kindeva Drug Delivery L.P. FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION
EP3861988A4 (en) * 2018-10-02 2022-06-29 Meijo University Educational Foundation Powder inhaler, method for assessing same, and use of same
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20200405700A1 (en) * 2019-06-27 2020-12-31 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
WO2021165348A1 (en) * 2020-02-20 2021-08-26 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
RS63725B1 (sr) * 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
CN116963715A (zh) 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
TW202241410A (zh) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 可經由定量吸入器遞送的藥物組合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
PL4175620T3 (pl) 2021-07-09 2024-08-05 Astrazeneca Pharmaceuticals Lp Kompozycje, sposoby i systemy do dostarczania leków w aerozolu
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
JP2024541470A (ja) 2021-11-25 2024-11-08 オレクソ・アクチエボラゲット アドレナリンを含む医薬組成物
JP2024545816A (ja) 2021-12-20 2024-12-12 アストラゼネカ・アクチエボラーグ エアロゾル薬物送達のための組成物、方法及びシステム
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
US20250345292A1 (en) 2022-04-28 2025-11-13 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (me) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
CA1201114A (en) 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
CA2123909C (en) 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
ATE233544T1 (de) 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5727333A (en) * 1994-02-09 1998-03-17 Kinerton Limited Process for drying a material from solution
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
AU706195B2 (en) * 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
ES2407135T3 (es) * 1996-11-11 2013-06-11 Meda Pharma Gmbh & Co. Kg Uso de (3S,2'R)-glicopirronio como medicamento
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
NZ337443A (en) 1997-03-20 2001-04-27 Schering Corp Preparation of powder agglomerates for the production of agglomerated dosage forms suitable for oral and/or nasal inhalation especially for pharmaceuticals of particle size less than 10 microns forming an inter particle bridge between agglomerates
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) * 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
EP1504760B1 (en) 1998-03-05 2008-07-09 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CN1158996C (zh) 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DE59914603D1 (de) * 1998-11-13 2008-02-14 Jagotec Ag Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP1139746A4 (en) 1998-12-22 2003-09-17 Univ North Carolina CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
JP2002541183A (ja) 1999-04-14 2002-12-03 グラクソ グループ リミテッド 医薬用エアゾール製剤
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
WO2001000312A1 (en) 1999-06-30 2001-01-04 Inhale Therapeutic Systems, Inc. Spray drying process for preparing dry powders
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT102343B (pt) * 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
KR100702878B1 (ko) 1999-10-29 2007-04-04 넥타르 테라퓨틱스 개선된 분산성을 갖는 건조 분말 조성물
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CA2405599A1 (en) 2000-04-13 2001-10-25 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US7442388B2 (en) * 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2000265583A1 (en) 2000-08-15 2002-02-25 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
ATE382335T1 (de) 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
DK1372608T3 (da) * 2001-03-30 2007-12-27 Jagotec Ag Medicinske aerosolformuleringer
EP1372751A1 (fr) * 2001-03-30 2004-01-02 Laboratoires Genevrier Neo-tissu cartilagineux greffable
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
EP1511500A4 (en) * 2002-06-12 2009-04-29 Epigenesis Pharmaceuticals Llc COMBINATION OF ANTI-MUSCARINIC AGENTS AND NONGLUCOCORTICOID STEROIDS
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
EP1542753B1 (en) 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
AU2003279070A1 (en) 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
AU2003279976B2 (en) * 2002-10-15 2007-10-11 Cryovac, Llc A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
US7238664B2 (en) 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
ES2316996T3 (es) 2003-07-28 2009-04-16 Boehringer Ingelheim International Gmbh Medicamentos para inhalacion, comprendiendo betamimeticos y un agente anticolinergico.
JP2007500150A (ja) 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用
MXPA06001047A (es) 2003-07-29 2006-04-24 Boehringer Ingelheim Int Medicamentos para inhalacion que comprenden betamimeticos y un anticolinergico.
EP1651224B1 (en) 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
RU2006127432A (ru) * 2003-12-31 2008-02-10 Сайдекс, Инк. (Us) Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии
RU2440813C2 (ru) 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
NZ548302A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2399279T3 (es) * 2004-06-18 2013-03-27 Novartis Ag Formulaciones de tobramicina para el tratamiento de infecciones endobronquiales
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
EP1861361A1 (en) 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
JP2008538758A (ja) 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2609429A1 (en) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
EP1898894A1 (en) 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp iv inhibitors for the treatment of respiratory diseases
CN103462943A (zh) 2005-07-15 2013-12-25 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
CN100560598C (zh) * 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PT1971369E (pt) * 2005-12-21 2009-10-20 Meda Pharma Gmbh & Co Kg Combinação de r,r-glicopirrolato, rolipram e budesonida para o tratamento de doenças inflamatórias
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
CA2653105A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2008217586A1 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
RU2482838C2 (ru) * 2007-12-13 2013-05-27 Новартис Аг Органические соединения
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
MX336414B (es) 2010-04-01 2016-01-19 Chiesi Farma Spa Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
JP2014504260A (ja) 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
KR20140012989A (ko) 2011-02-17 2014-02-04 시플라 리미티드 글리코피롤레이트 및 베타2-효능제의 조합
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
AU2011368334A1 (en) 2011-05-17 2013-11-21 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
EP2999460A1 (en) 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents

Also Published As

Publication number Publication date
TWI646980B (zh) 2019-01-11
TW201109051A (en) 2011-03-16
IL216468B (en) 2018-12-31
TWI539979B (zh) 2016-07-01
PL2435023T3 (pl) 2017-06-30
CN105193773A (zh) 2015-12-30
US20210186861A1 (en) 2021-06-24
SMT201600329B (it) 2016-11-10
BRPI1011508A2 (pt) 2016-03-22
US20110132357A1 (en) 2011-06-09
EP2435023A2 (en) 2012-04-04
BRPI1011229A2 (pt) 2016-03-15
EP2435025B1 (en) 2016-07-06
IL216466A0 (en) 2012-01-31
US9463161B2 (en) 2016-10-11
ZA201208100B (en) 2013-07-31
WO2010138884A3 (en) 2011-04-21
SI3111926T1 (sl) 2020-07-31
KR20120026075A (ko) 2012-03-16
CY2019031I2 (el) 2019-11-27
CN107412212A (zh) 2017-12-01
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
TW201919730A (zh) 2019-06-01
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
US20170112759A1 (en) 2017-04-27
ES2774367T3 (es) 2020-07-20
WO2010138862A2 (en) 2010-12-02
JP2018048150A (ja) 2018-03-29
RU2011154148A (ru) 2013-07-10
CN102458364A (zh) 2012-05-16
CY1122807T1 (el) 2021-05-05
CA2763936A1 (en) 2010-12-02
AU2010253770B9 (en) 2015-02-12
FR19C1040I1 (me) 2020-07-31
SMT202000077T1 (it) 2020-03-13
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
EP2435024A2 (en) 2012-04-04
EP3111926B1 (en) 2019-12-11
RU2016117972A3 (me) 2019-09-27
LTPA2019014I1 (lt) 2019-07-10
RU2016107464A3 (me) 2019-08-19
MX350163B (es) 2017-08-29
US20180125776A1 (en) 2018-05-10
PT3111927T (pt) 2020-03-03
FR19C1040I2 (fr) 2020-07-31
JP6348645B2 (ja) 2018-06-27
MX337126B (es) 2016-02-12
EP3111926A1 (en) 2017-01-04
CA2763941A1 (en) 2010-12-02
MX2011012685A (es) 2012-06-12
CY2019031I1 (el) 2019-11-27
KR20190049943A (ko) 2019-05-09
JP2016041713A (ja) 2016-03-31
HUS2100018I1 (hu) 2021-06-28
JP2017222706A (ja) 2017-12-21
SI2435024T1 (sl) 2016-10-28
AU2010253950B2 (en) 2014-12-04
AR076621A1 (es) 2011-06-22
PL2435025T3 (pl) 2017-08-31
US8808713B2 (en) 2014-08-19
US20250009652A1 (en) 2025-01-09
DK2435024T3 (en) 2016-10-24
EP2435023B1 (en) 2016-07-06
HRP20161101T1 (hr) 2016-11-04
HK1244669A1 (zh) 2018-08-17
LT2435023T (lt) 2016-09-26
JP6169639B2 (ja) 2017-07-26
TWI717511B (zh) 2021-02-01
EP2435025A2 (en) 2012-04-04
LT3111926T (lt) 2020-03-25
CN107412212B (zh) 2021-01-22
RU2011154083A (ru) 2013-07-10
US20170071850A1 (en) 2017-03-16
US20150017247A1 (en) 2015-01-15
US20190038548A1 (en) 2019-02-07
EP2435024B1 (en) 2016-07-06
HK1218867A1 (zh) 2017-03-17
AU2010253950A1 (en) 2011-12-08
ES2593429T3 (es) 2016-12-09
AU2010253776B2 (en) 2015-01-22
LUC00208I2 (me) 2022-10-07
PT2435024T (pt) 2016-10-13
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
HRP20200260T1 (hr) 2020-05-29
US20110023876A1 (en) 2011-02-03
TWI546094B (zh) 2016-08-21
HUS1900031I1 (hu) 2019-07-29
HRP20161098T1 (hr) 2016-10-21
SI2435025T1 (sl) 2016-10-28
ZA201108275B (en) 2023-04-26
DK2435023T3 (en) 2016-10-24
BRPI1011220A2 (pt) 2016-03-15
SMT201600327B (it) 2016-11-10
HUE031283T2 (hu) 2017-07-28
CN107669664A (zh) 2018-02-09
AR076807A1 (es) 2011-07-06
HK1247095A1 (zh) 2018-09-21
ES2772253T3 (es) 2020-07-07
CY2021012I1 (el) 2021-10-15
LUC00124I1 (me) 2019-06-13
CA2763939A1 (en) 2010-12-02
PT2435025T (pt) 2016-11-11
IL216467A0 (en) 2012-01-31
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
SI3106149T1 (sl) 2020-07-31
ZA201208102B (en) 2013-09-25
CN107669664B (zh) 2020-07-10
JP5823383B2 (ja) 2015-11-25
CY1118040T1 (el) 2017-05-17
HRP20200166T1 (hr) 2020-05-15
ZA201208101B (en) 2013-07-31
JP6189356B2 (ja) 2017-08-30
HUE029532T2 (en) 2017-03-28
JP6876734B2 (ja) 2021-05-26
TW201109049A (en) 2011-03-16
RU2015151358A3 (me) 2019-07-29
CY2021012I2 (el) 2021-10-15
DK3111926T3 (da) 2020-03-02
TWI633898B (zh) 2018-09-01
JP2015187108A (ja) 2015-10-29
SMT201600326B (it) 2016-11-10
RU2751771C2 (ru) 2021-07-16
JP2012528200A (ja) 2012-11-12
NO2019026I1 (no) 2019-06-13
CN105193773B (zh) 2018-12-11
BRPI1011229B1 (pt) 2020-10-13
JP2012528199A (ja) 2012-11-12
LUC00124I2 (me) 2019-12-27
PL3106149T3 (pl) 2020-06-01
PL2435024T3 (pl) 2017-01-31
WO2010138862A3 (en) 2011-04-14
KR20120015334A (ko) 2012-02-21
TW201808372A (zh) 2018-03-16
CA2763936C (en) 2017-10-03
US20110135737A1 (en) 2011-06-09
KR101748892B1 (ko) 2017-06-19
LTPA2021511I1 (me) 2021-06-25
DK2435025T3 (en) 2016-10-24
PT3111926T (pt) 2020-02-28
BRPI1011220B1 (pt) 2020-03-10
TWI792140B (zh) 2023-02-11
AR076806A1 (es) 2011-07-06
ES2592536T3 (es) 2016-11-30
LT3111927T (lt) 2020-03-25
HK1169026A1 (zh) 2013-01-18
JP5873013B2 (ja) 2016-03-01
MX2011012684A (es) 2012-05-23
PL3111927T3 (pl) 2020-06-29
CY1122749T1 (el) 2021-03-12
JP2012528792A (ja) 2012-11-15
RU2580315C2 (ru) 2016-04-10
JP5873012B2 (ja) 2016-03-01
BRPI1011229B8 (pt) 2021-05-25
PT3106149T (pt) 2020-02-19
CN102596176B (zh) 2017-09-19
HK1169027A1 (zh) 2013-01-18
ES2589135T3 (es) 2016-11-10
CN102458364B (zh) 2016-11-02
WO2010138868A3 (en) 2011-04-28
MX2020004077A (es) 2020-07-29
IL216467B (en) 2018-12-31
JP2018008942A (ja) 2018-01-18
JP2019108369A (ja) 2019-07-04
LT2435024T (lt) 2016-09-26
AU2010253770A1 (en) 2011-11-24
EP3106149B1 (en) 2019-11-20
SMT202000108T1 (it) 2020-03-13
RU2011152960A (ru) 2013-07-10
EP3111927A1 (en) 2017-01-04
MX2011012783A (es) 2012-06-28
AU2010253770B2 (en) 2014-12-11
HRP20200298T1 (hr) 2020-06-12
MX393243B (es) 2025-03-24
NL300995I2 (nl) 2019-10-29
PH12017500778A1 (en) 2018-01-22
LT2435025T (lt) 2016-09-26
RU2016107464A (ru) 2018-11-22
CY1118034T1 (el) 2017-05-17
TWI632926B (zh) 2018-08-21
WO2010138884A2 (en) 2010-12-02
RU2020102859A (ru) 2021-07-26
CY1122732T1 (el) 2021-03-12
HUE047823T2 (hu) 2020-05-28
SI3111927T1 (sl) 2020-08-31
KR20170104003A (ko) 2017-09-13
RU2713404C2 (ru) 2020-02-05
SMT202000109T1 (it) 2020-03-13
US10716753B2 (en) 2020-07-21
TW201700123A (zh) 2017-01-01
IL216466B (en) 2018-08-30
HK1169307A1 (zh) 2013-01-25
HUE047834T2 (hu) 2020-05-28
JP2015199735A (ja) 2015-11-12
HUE031229T2 (en) 2017-06-28
EP3111927B1 (en) 2019-12-11
TWI707700B (zh) 2020-10-21
NO2021019I1 (no) 2021-05-12
TW201642836A (zh) 2016-12-16
JP6492124B2 (ja) 2019-03-27
DK3111927T3 (da) 2020-03-09
TW201936174A (zh) 2019-09-16
EP3106149A1 (en) 2016-12-21
CN102753152B (zh) 2015-09-23
CY1118030T1 (el) 2017-05-17
TW202114642A (zh) 2021-04-16
WO2010138868A2 (en) 2010-12-02
CN102753152A (zh) 2012-10-24
US20110132356A1 (en) 2011-06-09
MX350164B (es) 2017-08-29
HRP20161102T1 (hr) 2016-11-04
US20190307676A1 (en) 2019-10-10
LT3106149T (lt) 2020-03-10
DK3106149T3 (da) 2020-02-24
CN102596176A (zh) 2012-07-18
RU2016117972A (ru) 2018-10-29
LTC2435024I2 (me) 2022-06-27
MX377778B (es) 2025-03-11
NL300995I1 (me) 2019-06-24
AU2010253776A1 (en) 2011-11-24
RU2580315C3 (ru) 2021-06-18
AU2010253950C1 (en) 2015-09-17
ES2774391T3 (es) 2020-07-20
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
TW201109050A (en) 2011-03-16
IL216468A0 (en) 2012-01-31
HUE047803T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
ME03631B (me) Sastavi za isporuku aktivnih agenasa u disajne puteve i povezani postupci i sistemi
EP2265126A4 (en) PROCESS AND COMPOSITIONS FOR THE CONTROLLED DELIVERY OF PHYTOCHEMICALS
EP2403447A4 (en) MICRO-CAPACITED BIOACTIVE AGENTS FOR ORAL RELEASE AND METHOD FOR THEIR USE
EP2747832A4 (en) AGGREGATE FORMULATIONS FOR DELAYED RELEASE
EP2544741A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
EP2526986A4 (en) DEVICE FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
EP2627382A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
EP2635260A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
EP2588130A4 (en) DISTRIBUTION THERAPEUTIC MEDICINE IN THE CNS
EP2558503A4 (en) COMPOSITIONS AND METHOD FOR RELEASING PAIN-STEEPING PEPTIDES IN THE BRAIN
EP2421587A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
EP2361647A4 (en) DRUGS OUTPUT DEVICE
EP2401024A4 (en) DEVICES, SYSTEMS AND METHOD FOR MAGNET-BASED RELEASE OF A THERAPEUTIC
EP2211956A4 (en) DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
EP2343982A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR CHARGING
EP2152290A4 (en) METHOD FOR THE ADMINISTRATION OF ANTI-IL-5 ANTIBODIES
BRPI0915411A2 (pt) partículas revestidas contendo agentes farmaceuticamente ativos
MX392150B (es) Moduladores de receptores canabinoides.
EP2667857A4 (en) ACTIVE RELEASE DEVICE
EP2643020A4 (en) ACTIVE RELEASE DEVICE
EP2488207A4 (en) POLYMERIC ANTIBODY RELEASE SYSTEMS
EP2220028A4 (en) HALOGENATED ANALOGS OF ANTIFIBROTIC AGENTS
EP2760353A4 (en) SYSTEMS AND DEVICES FOR REDUCING AND ASSOCIATING BONE
EP2596023A4 (en) COMPOSITIONS AND METHODS FOR IL-6 AND IL-21 ANTAGONISTS
EP2983789A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS